Venous thromboembolism and cyproterone acetate in men with prostate cancer: a study using the General Practice Research Database

被引:17
作者
Seaman, Helen E.
Langley, Stephen E. M.
Farmer, Richard D. T.
de Vries, Corinne S.
机构
[1] Univ Surrey, Dept Pharmacoepidemiol, Postgrad Med Sch, Guildford GU2 7WG, Surrey, England
[2] Royal Surrey Cty Hosp, Guildford, Surrey, England
关键词
cyproterone acetate; General Practice Research Database; prostate cancer; venous thromboembolism;
D O I
10.1111/j.1464-410X.2007.06859.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE To evaluate the risk of venous thromboembolism (VTE) associated with the use of cyproterone acetate (CPA) amongst men with prostate cancer. PATENTS AND METHODS Using data from the General Practice Research Database, cases of VTE were identified amongst men with prostate cancer. Four controls with no evidence of a VTE were selected for each case. The time from diagnosis of prostate cancer to first hormonal treatment, and from first hormonal treatment to VTE, was compared for different treatments. Adjusted risk estimates for VTE were derived from further analysis using a nested case-control study design amongst all men with advanced prostate cancer, qualified by evidence of hormonal treatment. RESULTS The time between diagnosis and first treatment was significantly shorter for men first treated with CPA than for men first treated with a luteinizing hormone releasing hormone (LHRH) analogue (adjusted hazard ratio 1.33, 95% confidence interval, CI, 1.06-1.67). When the first treatment was CPA, the treatment-free period after diagnosis was significantly shorter for men who later had a VTE than for those who did not. The case-control study yielded an adjusted risk estimate for VTE amongst CPA users that was significantly higher than amongst men who were prescribed an LHRH analogue or who had had an orchidectomy (adjusted odds ratio 5.23, 95% CI 3.12-8.79). CONCLUSION There was a greater risk of VTE associated with CPA, which might be due to differences in disease severity between users of different products. The clinical significance of this finding is unclear.
引用
收藏
页码:1398 / 1403
页数:6
相关论文
共 27 条
[11]   Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4) [J].
Hansell, A ;
Hollowell, J ;
Nichols, T ;
McNiece, R ;
Strachan, D .
THORAX, 1999, 54 (05) :413-419
[12]  
Hollowell J, 1997, Popul Trends, P36
[13]   VALIDATION OF INFORMATION RECORDED ON GENERAL-PRACTITIONER BASED COMPUTERIZED DATA RESOURCE IN THE UNITED-KINGDOM [J].
JICK, H ;
JICK, SS ;
DERBY, LE .
BRITISH MEDICAL JOURNAL, 1991, 302 (6779) :766-768
[14]   Validity of the General Practice Research Database [J].
Jick, SS ;
Kaye, JA ;
Vasilakis-Scaramozza, C ;
Rodríguez, LAG ;
Ruigómez, A ;
Meier, CR ;
Schlienger, RG ;
Black, C ;
Jick, H .
PHARMACOTHERAPY, 2003, 23 (05) :686-689
[15]   Validation of the diagnosis of venous thromboembolism in general practice database studies [J].
Lawrenson, R ;
Todd, JC ;
Leydon, GM ;
Williams, TJ ;
Farmer, RDT .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 49 (06) :591-596
[16]   Venous thromboembolism and cancer: Risks and outcomes [J].
Lee, AYY ;
Levine, MN .
CIRCULATION, 2003, 107 :I17-I21
[17]  
MOFFAT LEF, 1990, EUR UROL, V18, P26
[18]   EFFECTS OF CYPROTERONE-ACETATE AND A LONG-ACTING LHRH ANALOG ON SERUM-LIPOPROTEINS IN PATIENTS WITH CARCINOMA OF THE PROSTATE [J].
PAISEY, RB ;
KADOW, C ;
BOLTON, C ;
HARTOG, M ;
GINGELL, JC .
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 1986, 79 (04) :210-211
[19]   COMPARISON OF DIETHYLSTILBESTROL, CYPROTERONE-ACETATE AND MEDROXYPROGESTERONE ACETATE IN THE TREATMENT OF ADVANCED PROSTATIC-CANCER - FINAL ANALYSIS OF A RANDOMIZED PHASE-III TRIAL OF THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-ON-TREATMENT-OF-CANCER UROLOGICAL GROUP [J].
PAVONEMACALUSO, M ;
DEVOOGT, HJ ;
VIGGIANO, G ;
BARASOLO, E ;
LARDENNOIS, B ;
DEPAUW, M ;
SYLVESTER, R .
JOURNAL OF UROLOGY, 1986, 136 (03) :624-631
[20]  
PERRY J, 1978, OXMIS PUBLICATIONS